Article
Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.
PloS one - 1 Jan 2023
Aghemo Alessio, Persico Marcello, D'Ambrosio Roberta, Andreoni Massimo, Villa Erica, Bhagat Abhi, Gallinaro Valentina, Gualberti Giuliana, Merolla Rocco Cosimo Damiano, Gasbarrini Antonio
Abstract excerpt
INTRODUCTION: Glecaprevir/pibrentasvir (G/P) has demonstrated high rates (>95%) of sustained virologic response at posttreatment Week 12 (SVR12) in treatment-naïve (TN) patients with hepatitis C virus (HCV) infection and compensated cirrhosis (CC). Here, in a key real-world subset of TN Italian patients with CC, we evaluated the effectiveness and safety of 8-week G/P treatment, including subgroups of interest...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.